Cancer Clinical Investigation

癌症临床研究

• 批准号: 10674507
• 负责人: MARSHALL R POSNER
• 金额: $ 2.63万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674507
• 关键词: Area; Award; Back; Cancer Center Support Grant; Cancer Patient; Clinic; Clinical Trials Design; Collaborations; Direct Costs; Discipline; Doctor of Philosophy; Education; Fostering; Funding; Goals; Immune system; Immunooncology; Laboratories; Malignant Neoplasms; Mission; Paper; Patients; Peer Review; Process; Publishing; Research; Science; Therapeutic; Therapeutic Trials; Translating; Work; bench to bedside; cancer care; cancer cell; cancer clinical trial; cancer therapy; clinical development; clinical investigation; clinical translation; improved; innovation; medical schools; meetings; member; novel therapeutic intervention; preclinical development; programs; therapy development; treatment strategy; tumor microenvironment; working group

PROJECT SUMMARY/ABSTRACT – CANCER CLINICAL INVESTIGATION (CCI) PROGRAM The Cancer Clinical Investigation (CCI) Program of the Tisch Cancer Institute (TCI) is comprised of 45 members who share the common goal of advancing treatment science to ultimately improve the lives of patients with cancer. They represent 16 Departments and 14 Institutes at the Icahn School of Medicine. As of February 2019, CCI program members were awarded $13.7 million in direct cost funding, with NCI support of $3.2 million and peer-reviewed cancer related support of $7.7 million. In 2018, the program published 151 papers of which 20% were intra- and 20% were inter-programmatic. The core mission of the CCI Program is to leverage the TCI’s outstanding science and innovation to maximally impact cancer care through the preclinical and clinical development of novel therapeutic strategies. The program is comprised of two major scientific themes: (1) cancer cell intrinsic targets and (2) immuno-oncology (IO) and tumor microenvironment (TME) targets. The specific aims of the program are to: (1) develop cancer therapeutics, therapeutic approaches, and therapeutic trials directed at cancer cell-intrinsic targets, (2) develop cancer therapeutics, therapeutic approaches, and therapeutic trials directed at the host immune system and TME, and (3) foster TCI intra- and inter-programmatic collaborations that facilitate the clinical translation of TCI science through bench-to-bedside and bedside-to-bench approaches.

项目摘要/摘要 – 癌症临床研究 (CCI) 计划 Tisch 癌症研究所 (TCI) 的癌症临床研究 (CCI) 项目由 45 名成员组成 他们的共同目标是推进治疗科学，最终改善患者的生活 截至 2019 年 2 月，他们代表伊坎医学院的 16 个系和 14 个研究所。 CCI 计划成员获得了 1,370 万美元的直接成本资助，其中 NCI 提供了 320 万美元的支持， 2018 年，该项目发表了 151 篇论文，其中 20% 获得了 770 万美元的同行评审癌症相关支持。 是计划内的，20% 是计划间的。 CCI 计划的核心使命是利用 TCI 杰出的科学和创新，最大限度地发挥 该计划通过临床前和临床开发新的治疗策略来影响癌症治疗。 由两个主要科学主题组成：(1) 癌细胞内在靶点和 (2) 免疫肿瘤学 (IO) 和 该计划的具体目标是：（1）开发癌症疗法， 针对癌细胞内在靶标的治疗方法和治疗试验，(2) 发展癌症 针对宿主免疫系统和 TME 的疗法、治疗方法和治疗试验，以及 (3) 促进 TCI 项目内和项目间合作，促进 TCI 科学的临床转化 通过从凳到床边和从床边到凳的方法。